October 2012

Welcome

‘Autumn...the year's

last, loveliest smile’

Having just returned from Boston in

the fall, I‟m reminded of this quote

from William Cullen Bryant, long

time Editor of the New York Evening

Post.

Since our Spring Newsletter there

have been some other things to

smile about in the UK too - some

real boosts for the sector. Not least

the launch of The Biomedical

Catalyst – which sees £180 million

of Government funding to bridge the

„valley of death‟ for medical

breakthroughs, the Science

Ministers announcement just before

BIO in May of £250 million of BBSRC

grants not to mention two separate

investments in synthetic biology.

The Wellcome Trust has been busy

too – their partnership with MRC

which sees them investing £8

million in a new world class Stem

Cell Institute at the University of

Cambridge and the launch of their

£200 million fund to invest in

biotechnology start-up companies in

the UK and Europe. Plus their

collaboration with the Engineering

and Physical Sciences Research

Council (EPSRC) recently which saw

them launch a joint £30 million

initiative to find biomedical

engineering solutions to challenging

healthcare problems and the

EPSRC‟s own manufacturing

fellowships each worth £1 million.

The good news doesn‟t end there.

The latest report on the global

biotechnology sector from Ernst &

Young (Beyond borders: global

biotechnology report 2012) noted

that the sector „showed a second

straight year of increasingly stable

financial performance in 2011‟, with

the established biotech markets (the

USA, Europe, Canada and Australia)

registering more than 10% revenue

growth „for the first time since the

start of the global financial crisis.‟

The analysis also points out that in

2011 „overall funding exploded‟ as

biotechs raised a „staggering $33.4

billion…second only to 2000, when

the genomics bubble was at its

height.‟

That said, this increase was driven

by a handful of commercial leaders

with revenues in excess of $500

million that took advantage of low

interest rates to raise large sums of

debt so we shouldn‟t get carried

away. But good to see some major

positives.

Here at One Nucleus we continue to

do all we can to remain true to our

mission – to help maximise our

members global growth and

competitiveness.

I have just returned from AdvaMed

(see Pages 23 and 24) where I took

the opportunity to catch up with a

wide range of One Nucleus friends

and new contacts.

3 MassMEDIC

Tom Sommer, President MassMEDIC on

Recent Activities

28 Genesis 2012

One Nucleus‟ plans for Genesis 2012

9 First Sight Media

Mike Gilham, First Sight Media on Social Media - The

black hole of time?

Continued overleaf

Welcome October 2012 2

Of particular note were Tom

Sommer, CEO of MassMedic (see

our interview with him on Page 3),

Susie Kitchens, the new British

Consul General in Boston and Tony

Newton, ex Genzyme and now with

PGD out of Maryland who is

currently creating BioBrits. Susie

has been in situ for just over 5

weeks and has certainly hit the

ground running. She is busy

working on a Cambridge to

Cambridge initiative that I have

committed to support her on –

forging strong (er) than ever links

between the two Cambridge

communities. More on this as plans

develop. And Tony Newton, Chief

Commercial Officer at Personal

Genome Diagnostics

(www.personalgenome.com) who

recognises the consummate

advantage to knowing the right folk

on that side of the pond with his

launch of BioBrits. The group is a

very informal set of British life

science and healthcare individuals

who are based in the Mass area and

come together for informal

gatherings on a regular basis. Tony

is very keen for UK based

companies to feel free to access

this set when they are in Boston to

have a drink together and learn

from those already there who have

been there and done it and who

may open their address books to

support our members when in

town. He is planning these

gatherings monthly, with the first

on 25 October (Meadhall Boston,

5.30pm onwards). If you are

interested in connecting with him,

do click here: www.linkedin.com/in/

antonynewton

As many of you will know, the One

Nucleus team is always looking for

brighter, stronger and more

creative ways of doing things,

honing our member offer all the

time. With this in mind I‟m

delighted to introduce you to our

new microsite for Genesis 2012

website:

www.genesisconference.com. We

are collaborating extremely closely

with SCRIP Intelligence for Genesis

this year (see Page 28 and 29).

New Activities

In other exciting news, here‟s a

question for you: What do Sir Bruce

Ponder of Cancer Research UK,

Ruth McKernan Senior VP of Pfizer/

CSO of Neusentis and Dave

Tapolczy, CEO of MRC Technology

all have in common?

Answer: they are all on the

Advisory Board for our BRAND NEW

Cambridge based Conference which

will be taking place on 9 July 2013.

Check out Page 33 for more details

and to see the full Advisory Board

list.

This issue of the Newsletter also

sees us bringing you news of a

BRAND NEW service we are offering

members too. The One Nucleus

Dashboard aims to give all our

members the right information, at

the right time (for you) and in the

right place – see Page 29 for more

information.

Before I sign off, a quick reminder

and a pointer for those of you who

aren‟t yet One Nucleus members. A

reminder that One Nucleus remains

by far the largest membership

organisation for life science and

healthcare companies in Europe,

with over 470 organisations as

members and remain incredibly

proud to have each one of them in

our fold. The pointer is to our on-

line searchable member database

(the pink button on our website –

www.onenucleus.com) where you

can see for yourself who we have in

our One Nucleus family. This is

updated daily via Venture Valuation

so you are sure of the right details

each and every day.

I hope you enjoy reading our

Autumn Newsletter. Feedback is

always extremely positive and I

certainly hope it gives you a great

flavour of all the fantastic work

being done by our members for

regional and global impact and

success. The Newsletter has a

distribution of 8000 around the

globe so is definitely the place to be

name-checked! Talking of which...

our very newest member is Ricky

Martin, winner of this year‟s

Apprentice and Managing Director

of Hyper Recruitment Solutions. We

very much look forward to

supporting his endeavours and I

personally look forward to facing

the steely glare of Lord Sugar

himself at a Q & A meeting with

him in London on 23 October.

CEO

One Nucleus

‘Our very newest member is Ricky

Martin, winner of this year’s

Apprentice and Managing Director of

Hyper Recruitment Solutions’

Member News October 2012 3

A First for AdvaMed

In what has now become a regular feature, we talk to a One Nucleus

global partner organisation - MassMEDIC’s president, Tom Sommer, on

hosting AdvaMed 2012 in Boston, recent activities and ties with the UK

„As you can imagine we were

delighted to be hosts of AdvaMed

2012 particularly as it was the first

time the conference has been held

outside of Washington DC. Boston

being chosen is testament to the

strength of the medical device

community in Massachusetts and

the global reputation we have

developed. It gave us the

opportunity to showcase what the

region has to offer not just to the

US but also internationally. We saw

large numbers of overseas

delegates with big contingents from

the UK of course, but also Canada,

China, Switzerland and the rest of

Europe. Everyone went away with a

real feel for the area‟s

research capabilities,

investment commitment

and the high calibre

workforce not to say the

sheer volume of med tech

located in the state.‟

„One highlight of the

conference‟, added

Sommer, „was an

impressive event on the

Tuesday evening hosted by

the British Consulate-

General in Boston where we

heard from Lord Howe,

Parliamentary Under-

Secretary for Quality,

Department of Health.‟

„We were pleased to

welcome One Nucleus leadership

and members to the conference as

part of the UKTI‟s involvement –

without our strong UK ties this

would not have been so successful.‟

„We value the relationship with One

Nucleus as it provides us the

opportunity to point our members

in the UK‟s direction providing them

“a soft landing point”. We are

happy to be able to reciprocate and

provide support to One Nucleus

members wishing to crack the US

market by harnessing all the

resources available in the

Massachusetts area and providing

insight and links into other regions.‟

Going on to talk more about

MassMEDIC, Sommer added, „We

were founded in 1996 by a group of

like-minded medical device

company executives who identified

the potential for an organisation

solely focused on the very unique

interests of the Massachusetts‟s

vibrant medical technology sector.

We are now the largest regional

medical device association in the

US, and continue to drive success

and growth with the industry and

our members.‟

Sommer has led the organisation

since its start, overseeing day-to-

day operations and working closely

with the executive committee and

Board directors in developing its

policy agenda.

„Much of my time is spent as an

advocate for the industry, lobbying

and promoting policies that reflect

the unique interests of our

members. The hard work is paying

off and after several years of being

in defensive mode we are now

seeing positive changes to public

policies that had the potential to

impact the success and growth of

the sector. During the last year, we

have continued to play an active

role at state level on policy issues

such as repealing the “gift ban” law

that would have had a chilling

effect on both physicians and

companies.‟

„Unfortunately despite our every

effort we were unsuccessful in fully

repealing the imminent introduction

of a medical device excise tax, our

focus is now to ensure members

are briefed and prepared for

compliance in readiness for January

2013 implementation.‟

‘We value the relationship with

One Nucleus as it provides us the

opportunity to point our members

in the UK’s direction providing

them a soft landing point.’ Tom

Sommer, President MassMEDIC

Tom

Som

mer, P

resid

ent M

assM

ED

IC

Continued overleaf

Member News October 2012 4

Another area that Tom is

passionate about is the

organisation‟s commitment to

helping early stage companies

through MedTech IGNITE, an

initiative that provides free

mentoring to medical device

entrepreneurs at the early stages of

their company's conceptualisation,

formation and development. Tom is

proud that through IGNITE,

MassMEDIC have helped dozens of

companies progress to next stage

in their development.

And finally, asked about the

medical technology market moving

forward, Sommer concluded, „Set

against the new healthcare agenda,

the pressure will be on medical

device companies to develop

marketing strategies that not only

demonstrate safety and

effectiveness of their devices but

also the contribution they will make

to driving down the overall cost of

healthcare.‟ On reflection we

agreed this was a prediction equally

as applicable in the UK as it is to

the US.

One Nucleus Welcomes Steve Bates

as BIA’s New Chief Executive Steve Bates is the recently

appointed Chief Executive Officer of

the BIA and One Nucleus spoke to

him on the eve of his full

appointment on 1 September 2012.

„The raison d‟etre of the BIA is as

the voice for the sector, particularly

in government, and we plan to

continue to effectively represent

the industry as a whole. I am lucky

to be able to lean on my experience

at Genzyme but also prior to that,

working in UK government as

special advisor for John Reid MP. A

little known fact is I‟m the most

travelled special advisor in UK

government history, having worked

in seven departments but most

notably alongside Defence and

Home Office which gave me unique

insight into matters of animal

licensing as well as terrorism. I also

spent two years at the DoH, so

altogether I have a real

understanding for the “ins and

outs” of Whitehall.‟

Steve added „Having worked in

both government and biotech I

know I can be an effective voice for

the BioIndustry Association and I

am really looking forward to

working across the sector and with

government, academia and the

health service to enable bioscience

companies to succeed in the UK.‟

In terms of priorities, Steve

acknowledges there are many but

sees the following as issues

particularly critical to members and

where he will be pushing for

progress in the short term.

- „Citizens Innovation Fund report

which presents a plan to „crowd

source‟ new forms of funding for

innovative companies and will

benefit the biotech sector hugely.

The idea here is to enable the UK

public to invest in innovation, much

the same way as the French have

been invested in their biotech

sector in the past. The BIA will be

putting considerable weight behind

this to encourage adoption by

policy makers. One Nucleus

members may be interested in

seeing the report once published in

the autumn.‟

- „Medicines and Healthcare

products Regulatory Agency

(MHRA) consultation on Early

Access Scheme - this is one

element of the government‟s Life

Sciences Strategy proposal to boost

the sector and a scheme the BIA

will follow closely. We will be

making a detailed response to the

government‟s proposal after

running workshops and full

consultation with our members.‟

- „Similarly, the BioMedical Catalyst

Fund – this is a new fund coming

from government that will be used

for the benefit of the life science

community. The BIA has lobbied

hard for many years for this and I

am happy to take up the mantle

and make sure that it is practically

working for companies.‟

Ste

ve B

ate

s, C

EO

BIA

Continued overleaf

Member News October 2012 5

- „Animals in research – this means

working as a coalition not only

within the industry but outside with

academics and charities to

continually review that the public

have a realistic and sensible

understanding of the role of

animals in research for new

medicines.‟

Looking more to the future, Steve

says „it‟s such early days in the role

and I am still developing my

thoughts.‟ What he can say though

is „there is much regulatory debate

on how things might change not

only at a European and

International level but here in the

UK by the MHRA, DoH and Number

10 around adaptive licensing - how

things might change and become

easier for the life science sector.

Catching that wave and navigating

to a successful outcome will be all

important for our industry.‟

Steve is keen to stress that he is no

stranger to One Nucleus and its

members having spoken at many

events in his previous role as senior

director external affairs at Genzyme

and as an expert in market access

and policy. He sees his

appointment as a great chance to

continue and deepen his

relationship with One Nucleus

members. He also welcomes any

opportunity to get back to the

Cambridge Fenlands, with fond

memories of his undergraduate

days at Girton College and where

he moonlighted as a DJ on what

was then CNFM103 radio. Steve

points to other ex-students of

Girton College as important

contributors to the biotech policy

debate including George Freeman,

government advisor on Life

Sciences and Phil Hammond, GP,

comedian and regular contributor

on all things medical to Private Eye.

„I‟m no George Freeman, or Phil

Hammond but hopefully sit

‘I’m no George Freeman, or Phil Hammond but hopefully sit

somewhere in between!’ Steve

Bates, Chief Executive BIA

Imperial College London Collaboration

will Aid Malaria Vaccine Development Imperial College London is collaborating with the PATH Malaria Vaccine Initiative (MVI) and the International

AIDS Vaccine Initiative (IAVI) to guide the selection and prioritisation of malaria vaccine candidates. The collaboration will create a new central „reference lab‟, measuring, under

standardised conditions, the capacity of different vaccine candidates in human clinical testing to elicit an immune response aimed at protecting against deadly malaria parasites.

One obstacle to comparing the cell-mediated immunity elicited by different malaria vaccine candidates has been the lack of uniform validated techniques and processes used by different laboratories to

evaluate T-cell immunity. In an effort to identify a more consistent understanding of how multiple vaccine candidates were performing at a cellular level, IAVI and its

Human Immunology Laboratory

(HIL) at Imperial College London refined and validated specific tests, or assays, that measure vaccine-induced, cell-mediated immunity. „These tests can provide quantitative

information, such as how many cells responded to the vaccine, along with qualitative

information, such as the different cell types that were stimulated,‟ said Professor Gavin Screaton, Head of the

Department of Medicine at Imperial College London. „Both types of information can be important in determining the power of the overall vaccine-induced immune response.‟

„We‟re delighted to be hosting this work at Imperial, which builds on our longstanding fruitful

association with IAVI,‟ he said.

„We‟re also looking forward to working more closely with MVI as part of our commitment to vaccine research and international health.‟

Member News October 2012 6

AstraZeneca and Bristol-Myers

Squibb Expand Diabetes Alliance

We were delighted to announce in

our Spring Newsletter AstraZeneca

as the first large pharmaceutical

company to engage in our One

Nucleus Partner Programme. Since

then the Company has

strengthened its leadership position

of successful alliance in diabetes.

AstraZeneca and Bristol-Myers

Squibb Company announced in

June that Bristol-Myers Squibb

would acquire Amylin

Pharmaceuticals Inc for

approximately $7 billion, and that

following this acquisition,

AstraZeneca and Bristol-Myers

Squibb would enter into

collaboration arrangements, based

on the framework of the existing

diabetes alliance, regarding the

development and commercialisation

of Amylin‟s portfolio of products.

Profits and losses arising from the

collaboration would be shared

equally.

In August

AstraZeneca made

an initial payment

of approximately

$3.2 billion to

Amylin

Pharmaceuticals,

now a wholly-

owned subsidiary of

Bristol-Myers

Squibb, in

connection with the

expansion of the

diabetes alliance

between

AstraZeneca and

Bristol-Myers

Squibb.

AstraZeneca also

informed Bristol-

Myers Squibb of its

intention to exercise

its option to acquire

certain additional

governance rights over key

strategic and financial decisions

regarding Amylin‟s portfolio. The

rights to this option will become

effective once the applicable anti-

trust and competition approvals are

received by AstraZeneca. Upon the

exercise of the option an additional

payment of $135 million will be

made to Bristol-Myers Squibb.

Simon Lowth, Interim Chief

Executive Officer, AstraZeneca,

said: „The broadening of our

diabetes collaboration with Bristol-

Myers Squibb is another important

step towards creating a leadership

position in the treatment of a

disease that is reaching epidemic

proportions in many areas of the

world. We are looking forward to

working with the team at Amylin to

build on their success and

maximise

AstraZeneca‟s

and Bristol-

Myers Squibb‟s

combined capabilities to make

Amylin‟s innovative treatments

available to diabetes patients

across the world.‟

Lamberto Andreotti, Chief Executive

Officer, Bristol-Myers Squibb, said:

„The completion of our acquisition

of Amylin and the expansion of our

diabetes alliance with AstraZeneca

will increase and strengthen our

innovative portfolio of diabetes

medicines, extending its reach

across the spectrum of treatment

options. We are pleased to have

the opportunity to work together to

build on the innovative portfolio,

state-of-the art manufacturing

facilities and dedicated customer

focus that the talented people at

Amylin have created.‟

Nick Dunscombe, who heads up the

Alliance Management Centre of

Excellence at AstraZeneca,

responsible for the proactive

management of our partnerships

and the sharing of best practice,

added: „Signing the deal is just the

beginning and the success of the

ongoing partnership is our key

priority. At AstraZeneca we are

keen to continuously improve our

Alliance Management capabilities,

as an example we conduct annual

surveys, with our partners known

as “health checks”, and also

actively apply learning / best

practice from our partner. In this

way we also ensure that we are

meeting our partners‟ needs and

delivering upon our joint

commitments.‟

Nic

k D

unscom

be, L

eader , G

lobal A

lliance M

anagem

ent C

entre

Of E

xcelle

nce a

t Astra

Zeneca

Member News October 2012 7

Zyme Communications Ltd (Zyme), the public relations and marketing agency specialising in the life

science sector, has had a

particularly busy last quarter. New client wins have included MRC Technology, AbD Serotec and Cytoo, the new Zyme website has been launched (www.zymecommunications.com), and the company exhibited for the

first time at the ELRIG Drug Discovery 2012 conference. On the back of this growing business success, Zyme has recently announced the appointment of Sarah Jeffery to the post of Project

Director. Commenting on her new position, Sarah said: „My first project having recently joined Zyme is working with One Nucleus on this, the Autumn edition of the One Nucleus

Newsletter. We support Harriet and her team as communications advisors and editors of the bi-annual newsletter which goes to 8,000 recipients internationally. Nothing like being thrown in at the deep end, but it has been a great

opportunity to very quickly re-acquaint myself with this vibrant cluster. Within just a few days I had interviewed Thomas J. Sommer, President of MassMEDIC, the largest regional medical device

association in the United States, and gleaned a little known fact from Steve Bates, the BIA‟s new CEO on the eve of his first official day in post.‟

Harriet confirms „Our view here at One Nucleus is that

relationships are built

on mutual trust, respect and proven delivery. We have known Lorna, Zyme‟s MD, for a number of years and she and her team at Zyme

are the natural partner of choice to be involved in our bi-annual Newsletter‟s creation‟.

As a marketing and communications specialist, Sarah has over 20 years‟ experience leading growth, brand awareness and

strategic initiatives for healthcare companies – from life sciences through to clinical practice, most recently as Head of Public Relations &

Communications for The Practice PLC. „What really attracted me to Zyme was the breadth of its service offering and refreshing approach to

business. Zyme is not only a PR agency but has extensive experience in marketing and design, which really plays to my strengths in delivering integrated campaigns both in house and for

clients. I had worked with Lorna previously and I was absolutely delighted to be approached to join

the team.‟ To find out more, visit zymecommunications.com or contact info@zymecommunications.com

A Fresh Approach to Communications

Sara

h Je

ffery

, Pro

ject D

irecto

r Zym

e C

om

munic

atio

n

Member News October 2012 8

Novel cancer therapies firm,

Spirogen, has joined London‟s

fastest growing life science,

healthcare and technology hub. The

Queen Mary BioEnterprises (QMB)

Innovation Centre, London‟s first

completely new build facility for

early stage start-up and follow on

life sciences and biotechnology

companies, announced the

chemistry division of Spirogen as

their newest tenant in July.

One Nucleus member Spirogen,

founded in 2000, has one oncology

drug, SG2000 currently in Phase II

clinical trials, a platform technology

for highly potent Antibody-Drug

Conjugates (ADC), and

partnerships with Genentech, Celtic

Therapeutics and ADC

Therapeutics.

Dr Chris Martin, CEO of Spirogen

said: „The state of the art facilities

offered by QMB will have a

significant impact as we progress

our various programmes and

technologies. The ability of QMB to

provide office space alongside

laboratory space, which has been

tailored for our specific needs, was

a key factor in our decision to come

here.‟

The QMB Innovation Centre is able

to provide both conventional

incubator and grow on space in

London. Through the combination

of its initial base build

infrastructure design and the

subsequent overlay of commercial

lab fit-outs, QMB can offer both

chemistry and biology category 2

laboratory and office suites. This

flexibility allowed Spirogen suites to

be equipped with an air extraction

system incorporating eight low

electricity consumption chemistry

fume hoods, which were installed in

a joint design programme with

QMB.

Ramsay Richmond, Executive

manager of QMB commented: „We

are very pleased that Spirogen

have found with us, modern and

affordable commercial chemistry

labs inside London. Spirogen had

specific discovery chemistry needs,

but the Innovation Centre was able

to accommodate these in a joint fit-

out, illustrating the strength of a

modern, easily reconfigurable

building. This validates the faith of

both funders, QMUL and the GLA, in

supporting an infrastructure

intensive building inside London.‟

A Focus for Life Sciences Activity in the

UK Capital

Building the Community at Stevenage

Bioscience Catalyst

Against a backdrop of stellar

performance from Team GB at the

London 2012 Olympics, Stevenage

Bioscience Catalyst (SBC) has been

building a thriving community over

the summer.

In addition to the exciting news in

June that Cambridge University will

be locating a centre of innovation

at SBC, the facility now houses

several entrepreneurs and start-

ups, complemented by virtual

tenants and Aptiv Solutions. A key

ethos for SBC is to pull closer

together the constituent parts of

the UK life sciences innovation

ecosystem, and the University's

desire to tap into this validates the

model. The University was attracted

to SBC by its open innovation

approach and access to drug

development expertise from

GlaxoSmithKline and other

stakeholders, tenants and partners.

You can hear more from the

University at the inaugural

Stevenage Bioscience Catalyst

Open Innovation Summit, which is

taking place on 15 November 2012.

There's a 20% registration discount

for One Nucleus members via

www.eventbrite.com/

event/3821959584?ref=ebtnebtckt

Member News October 2012 9

Social Media - The black hole of time,

unless you know what you’re doing!

Social media can be your

commercial friend or foe. Applied

correctly, as part of a digital

marketing plan, it can deliver

exceptionally cost effective and

quantifiable results. However,

without careful planning, it can

suck hours from your day and

achieve nothing.

Firms have achieved success

through the use of social media,

website or video marketing

campaigns, but few companies

have grasped the competitive

advantage to be gained from using

all three together. A successful

blend of social media, website and

powerful video marketing can

deliver synergistic commercial

benefits.

Life science firms are reported to

engage in tactical on-line

campaigns but few have

demonstrated they have the in-

house skill set to create and

execute strategic campaigns. The

main difference between

these approaches is that

tactical online campaigns

deliver „a short-term fix‟,

whereas strategic, digital

marketing campaigns

deliver long-term benefits,

and allow planned

inclusion of video and

website strategies. Once a

core strategy is

established, tactical

campaigns may be added

for short-term benefit and

as a fast flexible approach

to tackle new topics.

The Art of War master

Sun Tzu once said

„Strategy without tactics is

the slowest form of victory

however tactics without

strategy is the quickest

way to defeat‟.

First Sight Media has the expertise

to help life science firms develop a

strategic digital marketing plan

combining these three marketing

tools, to help companies to get

ahead of their competitors.

Video marketing can include

capturing and streaming, live

webinars, with live Q&A from e-

delegates, on-demand webinars,

corporate videos, capturing

exhibition and conference plenary

speakers and video clips for

inclusion within the client website.

Recent clients include One Nucleus,

Roche, Boehringer Ingelheim, and

British Equine Veterinary

Association.

For more information please

contact Mike Gilham at First Sight

Media on 0800 072 8753 or

mikegilham@firstsightmedia.co.uk.

Alternatively please visit

www.firstsightmedia.co.uk

Mik

e G

ilham

, Sale

s D

irecto

r Firs

t Sig

ht M

edia

Member News October 2012 10

UCB Encourages Tomorrow’s Medicine Discoverers

UCB opens its labs to pupils and hopes to ignite a passion for science and in turn generate more UK science graduates There can be few GCSE or A-level students who reply when asked about career plans, „I‟d like to be a medicine discoverer,‟ but through a

new scheme between UCB and local schools that may be about to change.

The drug company UCB, renowned for its central nervous system and inflammatory treatments, opened its research laboratories to around 30 science students in July and plans to send UCB scientists out to

teach at local schools. The company has its UK headquarters in Slough, Berkshire, where it also hosts its world centre for research

into immunology. Some 400 scientists work at the centre looking at conditions such as

rheumatoid arthritis, lupus and osteoporosis.

UCB invests heavily in R&D, especially within the UK where they are one of

the top R&D investors. But cash isn‟t the

only way to invest, and as part of UCB‟s long term

commitment to UK life sciences the company is keen to boost science skills and science education and help secure a positive environment for research and development. To display this commitment, UCB

launched „Work In Science Week‟ where GCSE and A-level science students were immersed into the world of industrial research science,

in a hands-on interactive environment.

The UK has a long history as a world leader in many fields of research, producing over 10% of global scientific output with only

1% of the global population. But despite a wave of educational reforms in the UK over the past decade, fewer school pupils are choosing to study science and maths beyond the age of 16. UCB

hopes that this project can encourage young scientists to carry on a very British tradition.

BioFocus, the integrated drug discovery partner based in Cambridge, UK, has signed two new collaboration agreements with

Japanese company Ono Pharmaceutical in recent months. The first focuses on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma. The second

agreement, announced in early

September centres on discovering novel drugs in the field of CNS disorders. Adding to its drug discovery capabilities, BioFocus has signed a

strategic alliance with Activiomics, allowing BioFocus to offer the company‟s proteomics services to its customers to improve identification of novel targets for

drug discovery and biomarkers for diagnostics. Activiomics proprietary technology, TIQUAS (Targeted In-depth QUAntification of cell

Signaling), provides valuable insights into which proteins or pathways have been activated following a cell signaling event, information that is generally not accessible using conventional

expression analysis. The technology

has application in a range of therapeutic areas including oncology, inflammation and metabolic disease. A further development for the

company, as part of its strategy to maintain its position as a leading provider of screening services, was the decision to select Titian Software‟s industry-leading Mosaic

sample management software to provide fast and easy access to BioFocus‟ 900,000 compounds, one of the largest HTS compound

collections of any CRO in the world. Kate Hilyard, VP Biological Sciences of BioFocus commented, „Further developments in infrastructure and equipment are in the pipeline to support what will become a single,

fully consolidated screening centre

at our Chesterford Park site by the end of 2012.‟

BioFocus Signs Two New Collaborations, Expands Drug

Discovery Offering and Enhances Screening Library

Member News October 2012 11

Engineering Design in Cambridge Argon Design is a design services

consultancy based in Cambridge,

UK, providing high technology

product design and development

for their clients, which range from

entrepreneurial start-ups to

established multinational

organisations.

With a focus on electronic product

design, including both hardware

and software disciplines, Argon

Design have particular expertise in

the areas of signal processing,

image and video processing,

multimedia, networking and in

solving complex algorithmic

problems.

The Company was founded in 2009

by serial entrepreneurs Steve

Barlow and Alan Scott, who

between them have over forty

years of experience in running

design consultancy businesses.

Being based in Cambridge allows

Argon Design to attract and recruit

the best „Google quality‟ engineers,

both from the local supply of

graduates and from further afield

within the UK and Europe. For

projects that require a wider range

of disciplines such as PCB

manufacture and assembly,

mechanical design or product

styling, Argon Design can draw on

a network of trusted partner

companies many of which are

based in the Cambridge area.

Argon Design uses its experience of

managing the product development

process to assemble the strongest

possible team of specialist design

and manufacturing resources

according to each client‟s priorities.

Argon Design‟s CEO, Alan Scott,

explained: „Argon Design is

delighted to join the One Nucleus

Partner Programmme. We have

long been enthusiastic advocates of

partnering as a means of building a

network of complementary

engineering skills across a range of

disciplines. This approach allows us

to bring best in class design skills

and technology to bear for each

client project.‟

Client projects typically include a

mixture of design functions

covering some or all of the

following areas – requirements

specification, system architecture,

analogue and digital board level

design, embedded and application

software, RTL design, FPGA design,

processor design, algorithm

development, signal processing and

image processing. In only three

years, Argon Design has

established a portfolio of

international clients, including

companies in the USA, Far East and

Europe.

For further information visit

www.argondesign.com or call Alan

Scott on 01223 422 355.

Syne qua non (SQN) is a

UK based leading data

management, statistical

reporting and electronic

data capture (EDC)

specialist service provider

and is recognised in

helping its many customers

to achieve their product

development goals through

innovative, quality based

technology and processes,

supported by an

experienced team of

professionals.

SQN is a long-term trusted partner

of many global pharma, biotech,

medical device, consumer health

and animal health focused

companies as well as academic and

health care providers. Together

with other specialist CRO partners,

SQN also provides fully integrated

clinical services capability

supporting local or

international trials where

required.

SQN recently announced

a significant enhancement

to their EDC and Clinical

Trial Management

System, Syne-clin. A

senior clinical research

professional described

Syne-clin as delivering

the ease of use and

functionality that many

envisaged EDC should have

delivered when it was first

introduced decades ago.

Syne qua non - Leading the way in Data

Management, Statistical Reporting and EDC

Continued overleaf

Member News October 2012 12

SQN have incorporated the wishes

and feedback from many involved

in clinical research, involving

hundreds of clinical trials hosted in

many countries. Rapid study start

up coupled with innovative PDF

based eCRFs with a paper look and

feel, simplify the data collection

process. Advanced real-time data

validation and flexible drill down

reporting through innovative

project dashboards are additional

reasons why the system is being

received so positively across the

industry.

A number of One Nucleus member

companies are working with SQN

on a range of projects ranging from

development consultancy through

to full service clinical trial

management, data management,

EDC, statistics and reporting.

Preferential rates are available for

One Nucleus members. If you are

interest in hearing more about SQN

and how they might add value to

your development planning then

they will be happy to discuss your

needs with you.

For more information please

Contact Karen Grover on 01379

644449 or email at

karen.grover@synequanon.com.

Alternatively please visit

www.synequanon.com

Horizon Discovery announced in

July that it is collaborating with

Bayer Pharma AG, using its

precision genome editing

technology, GENESIS, to develop

preclinical cell line models to

support Bayer‟s oncology research

and development programs. The

aim of the collaboration is to deliver

high quality cell lines that more

accurately model the disease-

relevant mutations found in human

tumors.

Kam Dhaliwal, Director of Business

Development, Horizon, said: „We

look forward to leveraging our

genome engineering expertise to

assist Bayer in finding novel

potential drug candidates to

address cancer. We are delighted

that Bayer selected

Horizon to

collaborate on its

drug discovery

programs, in

recognition of our

oncology disease

expertise.‟

Horizon also

recently

announced its

collaboration with

Domainex, to

support

Domainex's lead

optimisation

oncology

programme, TBK1/

IKKε, which is

being run in

conjunction with

the Institute of

Cancer Research,

London. Horizon

will support the

programme by

profiling a number of lead

compounds against a panel of

its X-MAN isogenic human cell

lines modeling the mutations

found in cancer cells.

Profiling of Domainex‟s lead TBK1/

IKKε dual inhibitor molecules

against these cell lines will enable

identification of the effect of

individual mutations on drug

activity and resistance, and

prediction of which patient sub-

groups will respond. This will help

guide the medicinal chemistry

optimization program and will

provide important patient

stratification data for future

partnering.

Aside from research collaborations,

Horizon recently announced an

agreement with ATCC, the

American Type Culture Collection

(ATCC), under which ATTC has non-

exclusive global licensing and

distribution rights for panels of

Horizon‟s X-MAN cell lines. The

agreement covers distribution to

ATCC‟s academic and not-for-profit

customers as a part of or in

conjunction with ATCC Tumor Cell

Panels, for non-commercial

research only, and excludes

distribution in Japan or distribution

of X-MAN isogenic cell lines in

isolation.

Horizon Partners with Bayer, Domainex and ATCC

Chris

Torra

nce, C

SO

, and D

arrin

Dis

ley, C

EO

, Horiz

on D

isocvery

Member News October 2012 13

Sim

on S

axby, C

EO

Selc

ia

As a part of the acquisition of

Cellzome in May this year,

GlaxoSmithKline announced that it

intended to facilitate the creation of

a spin-off company, which would

hold the rights to certain of

Cellzome‟s assets that GSK itself

did not wish to progress. Cellzome‟s

activities at its Chesterford

Research Park laboratories have

now ceased, but in the meantime a

small team of drug discovery

scientists previously with the

company have formed a new

venture, Autophagix, to exploit

these assets.

Autophagix is based in the Mansion

at Chesterford Research Park and

will focus on developing small

molecules that enhance autophagy.

„What is becoming clear is that the

process of autophagy can often go

wrong, either because of your

genes, your environment, or most

likely a combination of both,‟ said

Dr Alan Watt, CEO of Autophagix.

„Modulating autophagy has great

potential for the treatment of a

number of inflammatory diseases‟.

In addition to seeking

funding to develop the

Cellzome assets, the

Autophagix team is also

looking to capitalise on

their extensive drug discovery and

development experience by offering

to manage the progression of

molecules for other organisations.

Cellzome Spins Out as Autophagix

The A

uto

phagix

Team

Selcia Exploits In-house IP with Demerger Move

Selcia Limited, the globally active

contract research organisation

(CRO), announced the demerger of

all internally generated intellectual

property into two new companies at

the end of July.

CEO, Simon Saxby,

commented: „The move

will enable us to exploit

internally generated IP

efficiently and remain

focussed on our

successful core CRO

business. Demerging our

mitochondrial

dysfunction and novel

non-cyclosporin

cyclophilin inhibitor

molecule programmes

into Mitopharm, and our

anti-infective

programmes into Selcia

Pharma, will also allow

us to raise investment

capital more easily. We

are in discussions with a number of

potential partners and expect to

sign at least one licensing

agreement in 2012.‟

The first half of the year has seen

activity across both of Selcia‟s

operations: 14C custom

radiolabelling and integrated drug

discovery. The Radiolabelling

Division celebrated 20 years of

radiosynthesis at the Ongar, UK

headquarters while the Discovery

Division continued to develop and

promote its CEfrag drug discovery

platform and signed agreements

with a number of pharma partners,

including Heptares.

Member News October 2012 14

TTP Labtech’s comPOUND is at the Heart

of the University of Nottingham’s

Managed Chemical Compound Collection The University of

Nottingham‟s Managed

Chemical Compound

Collection (MCCC) offers

rapid access to more than

100,000 diverse drug-like

small molecules for high

throughput compound

screening. This fully

automated, state-of-the-

art facility is provided by

TTP Labtech‟s comPOUND

sample store and

comPILER tube-to-plate

processing system. This

facility is key to the University‟s

drug discovery research and to

provide services to its pharma/

biotech industry partners.

Prof Peter Fischer, Director, Centre

for Biomolecular Sciences,

University of Nottingham,

commented, „Worldwide

pharmaceutical companies are

turning to academic partners to

support compound screening for

drug R&D. The long-term vision is

to provide a unique compound

collection attractive to academic

and pharma partners –

especially SMEs without

their own collections‟.

„We were looking for an

integrated compound

storage and handling

system that would

increase throughput,

maintain long-term

compound integrity,

improve reliability with

complete inventory control

and unattended

operation‟, he continued.

TTP Labtech‟s comPOUND

and comPILER form a

compact and secure

modular system that

minimises the initial

investment in capital

equipment, yet still allows you to

expand library size and throughput

when required.

Significant healthcare investments

were made by Imperial Innovations

Group in July. PsiOxus

Therapeutics, a development-stage

biotechnology company that is

using non-traditional approaches to

develop novel therapeutics for

cancer and wasting diseases, raised

£22 million in a funding round led

by Imperial Innovations alongside

Invesco Perpetual, SR One and

Lundbeckfond Ventures. PsiOxus

will use the funding to advance the

clinical development of ColoAd1, a

potent, broad-spectrum anti-cancer

therapeutic capable of selectively

destroying tumour cells at minute

concentrations.

Cell Medica, a clinical-stage cell

therapeutics business, raised £17

million from Imperial Innovations,

Invesco Perpetual and the Cancer

Prevention & Research Institute of

Texas. Cell Medica, which is

developing technology based on the

selection, activation and expansion

of immune cells, specifically T-cells,

to prevent and treat a range of

diseases will use the funds to

advance its Cytovir immune-

reconstitution products towards

commercialisation, and to advance

clinical development of its Cytorex

EBV cancer therapy for the

treatment of Epstein-Barr Virus

related cancers.

Imperial Innovations builds and

invests in technology and

healthcare companies based on

research developed

at or associated

with Imperial

College London,

Cambridge

University, Oxford

University and

UCL. The

investment group

is based in London,

with offices in

Cambridge at

ideaSpace and the

Babraham

Research Campus.

Imperial Innovations Leads investments

in PsiOxus Therapeutics and Cell Medica

Member News October 2012 15

JSW Life Sciences (JSW), the

largest independent CRO in Austria,

performs both preclinical and phase

II-IV clinical research. Over more

than a decade, the preclinical

group‟s formidable experience has

focused on drug development for

neurodegenerative diseases. JSW‟s

reputation in the CNS field is

further enhanced by its capabilities

in preclinical efficacy studies

including in vitro molecular and

cellular analysis, proprietary in vivo

transgenic mouse and rat models,

and their associated analytics.

QPS is a GLP/GCP-compliant CRO

whose linearly integrated core

competencies include:

DMPK

Toxicology

Bioanalysis

Translational Medicine

Early Stage Clinical Research

Phase II–IV Clinical Research

The acquisition of JSW greatly

extends QPS‟s capabilities to

address new, as well as established

drug targets, in the CNS space.

Laboratories and testing facilities

are located in USA, Europe, India

and Pacific Asia.

For further information please

contact fabien.du.fraisse@qps.com

and visit www.qps.com

QPS Acquires JSW Life Science, Leading

Specialists in CNS Diseases, to establish QPS JSW

ICON, a global provider of

outsourced development services to

the pharmaceutical, biotechnology

and medical device industries,

announced plans to further expand

its UK hospital-based presence on

the Manchester Royal Infirmary

Campus. ICON has secured a

40,000 square foot pre-let at

Citylabs, a newly developed

biomedical centre of excellence

which was formerly the Manchester

Royal Eye Hospital.

ICON currently operates a state-of-

the-art, hospital-based Clinical

Pharmacology Unit on the

Manchester Royal Infirmary

Campus, where it will continue to

run its Phase I operations until fully

transitioning into the new, larger

Citylabs facility, currently targeted

to open in Q4 2013. Along with

ICON's Translational Medicine

Research Centre, Citylabs will

feature biohealth organisations,

including the Central Manchester

University Hospitals NHS

Foundation Trust, The University of

Manchester and other commercial

research organisations.

„We are pleased to be

expanding our early phase

development services

through the establishment of

a Centre of Excellence for

Translational Medicine in

Citylabs,‟ commented Dr.

Mario Rocci, President, ICON

Development Solutions. „This

expansion will enable ICON to

increase the capacity of its Clinical

Pharmacology Unit in Manchester

as well as the scientific services

that are essential in providing a

world class offering.‟

For further information please visit

www.iconplc.com

ICON Announces Plans to Expand Hospital-

based Presence for Translational Medicine

Member News October 2012 16

Promega recently

launched NanoLuc,

a novel luciferase

that is smaller,

brighter, and more

versatile than any

previously available

bioluminescent

enzyme. Its

attributes provide

new capabilities in

reporter assays with

potential in

biologically complex

applications that

require greater

sensitivity.

NanoLuc technology includes a

novel substrate, furimazine,

developed by Promega organic

chemists and a unique enzyme

developed by Promega researchers

using directed evolution techniques.

Its unparalleled small size allows

for enhanced viral delivery and

protein fusion applications, and it is

easily secreted from cells. The

enzyme is two orders of magnitude

brighter than either firefly (Photinus

pyralis) or Renilla reniformis

luciferases resulting in better

performance in hard to transfect

cells. NanoLuc also demonstrates

outstanding performance in more

physiologically relevant models

including complex biological

samples.

With add and measure

simplicity and a stable

signal, NanoLuc Luciferase

can be scaled from bench-

top to high-throughput

screening applications

with no modifications.

Promega has developed

twelve plasmid versions of

NanoLuc Luciferase, to

address the application

needs of a 'next-gen'

genetic reporter. This

includes NanoLuc-PEST

(NlucP), which closely

couples protein

expression to changes

in transcriptional

activity and increased

signal-to-background

ratios. For a secreted

reporter, a NanoLuc

Luciferase construct

has been prepared by

fusion to an N-terminal

secretion signal

(secNluc). Using the

Nano-GloT Luciferase Assay

Reagent, luminescence is linear

over a 1,000,000-fold concentration

range with a signal half-life ≥2

hours.

Promega Develops NanoLuc Luciferase

for Advanced Reporter Assays

Pharmidex, a CRO delivering CNS

and ADMET solutions to its clients,

has had a number of developments

recently. In June 2012, Pharmidex

expanded its business development

activity by securing offices at the

London Bioscience Innovation

Centre.

The Company is increasing its in-

house capabilities:

Establishing a zebrafish facility

in collaboration with Evotec and

the Royal Veterinary College.

Expanding its service offering by

acquiring bio-imaging

capabilities for application in

CNS and oncology studies.

Pharmidex is involved in a number

of new collaborations:

The Company was successful as

a partner in two awarded FP7

grants. One of these grants is

for the BIOtrachea project,

working with University College

London and 12

other partners

across Europe

for the

replacement of

organs using

synthetic materials. The second,

„Imaging of Neuroinflammation

in neurodegenerative diseases‟,

is with 27 partners from centres

of excellence across Europe and

UK.

In August 2012, Pharmidex was

awarded a Biomedical Catalyst

feasibility award together with

Hypha Discovery.

Recent Developments at Pharmidex

Member News October 2012 17

MRC Technology, based in London,

has launched its fee free Antibody

Engineering service for

humanisation of antibodies. The

service capitalises on CDR grafting

technology developed at the MRC,

and proprietary tools to deliver the

optimum antibody configuration.

Other engineering services offered

by MRC Technology include affinity

maturation and biophysical

characterisation.

The Antibody Engineering service is

carried out by MRC Technology‟s

BioTherapeutics team, part of MRC

Technology's Centre for

Therapeutics Discovery (CTD)

which works on early stage small

molecule drug discovery and

antibody engineering projects. The

team has already humanised more

than 50 antibodies, and its

development work has delivered

two marketed drugs (Tysabri and

Actemra), with a further six,

including Vedolizumab, in clinical

trials and another two in preclinical

studies.

MRC Technology has also launched

several collaboration projects within

the past few months, including a

project with the University of

Warwick to develop inhibitors of

inwardly rectifying potassium

channel kir7.1, for the treatment of

postpartum haemorrhage, and two

new collaborations with the William

Harvey Research Institute, Queen

Mary University of London (QMUL).

The QMUL projects will exploit G-

protein coupled receptors (GPCRs)

identified as effectors of

endogenous resolution of

inflammation, with the aim of

developing therapeutics for e.g.

chronic inflammation of the joints

or vascular inflammation, with

fewer side effects as they mimic

the way the body naturally resolves

inflammation.

MRC Technology Launches Antibody Engineering Service and Signs New Collaborations with Major

UK Academic Research Institutes

Good News for MedImmune

MedImmune, the global biologics

arm of AstraZeneca, is at the

forefront of groundbreaking

biotechnology research and

development. MedImmune

programmes now make up over

40% of AstraZeneca‟s overall

pipeline, the MedImmune pipeline

having grown from 40 assets in

2007 to more than 120 candidates

currently.

In April, an innovative collaboration

was announced between

MedImmune and Amgen to co-

develop five monoclonal antibodies

from Amgen‟s clinical inflammation

portfolio. The collaboration has the

potential to benefit the lives of

patients suffering from a range of

conditions, such as, asthma,

Crohn‟s disease, psoriasis, psoriatic

arthritis, systemic lupus

erythematosus and ulcerative

colitis.

In July, it was announced that the

UK is planning to introduce routine

flu vaccination for all children

between the ages of two to 17 from

the autumn of 2014, with

MedImmune‟s intranasal flu

vaccine, FluMist (Fluenz in Europe)

as the vaccine of choice for the

programme. The decision to offer

such a routine programme for

children is the first of its kind

anywhere in the world and is

expected to bring benefits, not only

for vaccinated children, but also in

reducing serious illness and deaths

in the wider population.

Member News October 2012 18

Oxford University Press (OUP) is

offering One Nucleus Members 10%

off all advertisements, in their

highly respected Life Sciences and

Medical journals.

OUP publishes over 280 journals,

50 of these within Life Sciences,

spanning a wide range of

subjects including bioscience,

biology, botany, genetics,

ecology, and more. Highlights

include Nucleic Acids Research,

Human Molecular Genetics,

Bioinformatics, Protein

Engineering Design & Selection,

Annals of Botany, and Molecular

Biology and Evolution, among

others.

OUP‟s highly cited, high-impact

and prestigious medical

journals include 68 titles across

a variety of fields from

oncology, infectious diseases,

cardiology, and nephrology, to

reproductive medicine,

rheumatology, anaesthesia and

geriatrics. Highlights include

the Annals of Oncology, Clinical

Infectious Diseases, Journal of

Infectious Diseases, and the

Journal of Antimicrobial

Chemotherapy, among many

others.

OUP‟s journals appeal to those

working in both clinical and

research settings. Also, books

content published by OUP can be

repackaged to suit your educational

and promotional needs in both print

and online. Articles, or book

chapter reprints, can be useful

promotional tools.

To get critical research and clinical

findings direct to the professionals

that need to see them, you could

consider publishing a

supplementary issue to a relevant

journal. These meet the same

editorial standards.

To find out more about the above

titles, or the advertising and

sponsorship opportunities available

in partnership with OUP, please

contact

steve.simmonds@oup.com or visit

www.oxfordjournals.org/corporate

Advertising Discounts now available to

all One Nucleus Members

Ste

ve S

imm

onds, A

dvertis

ing S

ale

s M

anager O

UP

Commenting on becoming a Silver

member, Pierre Socha, Investment

Manager, Seed Funds said,

„Amadeus Capital Partners is

pleased to be associated with One

Nucleus which is a vibrant player in

the European life science industry.

With investment focus on medtech

we foresee significant synergies

and look forward to a high level of

interaction with other members.‟

Amadeus Capital Partners is one of

Europe's leading technology

venture capital firms. Since its

inception in 1997, the firm has

backed nearly 80 companies in

industries that include

communications and networking

hardware and software, cleantech,

medtech, computer hardware and

software, media, and e-commerce.

Amadeus manages funds with total

commitments of £500m. Global

businesses built by the firm include

CSR plc (LSE:CSR), the leading

producer of single chip bluetooth

radios for short range connections,

and Solexa Ltd, the developer of

next generation genetic analysis

systems, merged into Illumina, Inc.

(ILMN) to create the world-leader

in gene-sequencing technology.

For more information, please visit

www.amadeuscapital.com

Amadeus Capital Partners joins One Nucleus

Pie

rre S

ocha, In

vestm

ent M

anager, S

eed F

unds

Member News October 2012 19

The pharmaceutical industry is in a

state of evolution. Many

blockbuster drugs that have

supported the industry well

financially over the last few

decades no longer have patent

protection, allowing generic

products to enter and de-value the

market. The use of generic

substitutes for branded products is

being actively encouraged by the

NHS to help reduce spend on drug

treatments whilst enabling an ever

growing number of patients to

receive care. This will deliver some

of the savings needed to fill the

£10bn NHS funding gap by 2015.

With increasing use of these

generics, regulatory authorities

such as the MHRA are now viewing

these as the „standard of care‟,

creating higher hurdles for any

pharmaceutical company

attempting to develop improved

follow-on treatments that can be

proven to be cost-effective to the

healthcare system.

Outlook

This has driven R&D functions of

many pharmaceutical companies

and Biotechs to narrow their focus

and begin to look at niche

opportunities in disease areas

previously overlooked as too

challenging or not having enough

patients to deliver a reasonable

return. These opportunities will be

looking at very specific patient

criteria that correlate with the

planned treatment and reflected in

their eventual marketing

authorisation and indicated use if

successful.

Thus, it is essential for the industry

to have a better understanding of

the patient population for a

particular disease, and this needs

to go deeper than basic incidence

or prevalence data currently used

today to more detailed sub-

populations that highlight specific

attributes, co-morbid conditions

and risk factors.

With this knowledge, treatments

can be targeted toward patient

profiles most likely to benefit

from the new treatment, thus

improving chances of a

successful outcome. This sets

the scene for more refined

clinical trial plans with reduced

numbers of patients in the trial,

reduction in overall costs and

shortened development times

for new treatments. From a NHS

perspective, this detailed

patient population information is

ideal when reviewing new

healthcare technologies to

identify the patient group that

will benefit the most and set a

suitable reimbursement price.

Solution

Basic information already exists

from various patient groups,

such as the Alzheimer‟s

Association, for prominent and

well-understood disease areas.

However, this is inadequate for

a large number of diseases and

disorders where information is

limited. To gain more relevant

patient detail, information needs

to be gathered from the many

patient registries and

epidemiology studies that look

specifically at clinical attributes,

risk factors and outcomes.

A new resource, the Epiomic

Segmentation Database, has

emerged to provide this missing

insight and form the building

blocks of patient segmentation.

It is a web-based tool for

healthcare professionals who

require more intimate

understanding of populations

affected by particular conditions.

It offers a reliable, evidence-based

source of patient populations that

goes beyond basic prevalence to

include essential conditions and

patient attributes for over 120

diseases. For access to this tool or

more information on the types of

information it can provide, please

contact sales@epiomic.com or see

our website www.epiomic.com

For further information on Black

Swan Analysis please contact

chrisopher.ehinger@blackswan-

analysis.co.uk or see our website

www.blackswan-analysis.co.uk

Quantifying Patient Segments is Key to Healthcare Innovation and Securing the Future of Healthcare

Member News October 2012 20

MEPC has sold Granta Park for a sum in the region of £127 million to the American biotech property firm BioMed Realty Trust, Inc. (NYSE:

BMR). The acquisition will see BioMed take control of 472,200 sq ft of space including 11 buildings at the park, which is home to some of the world‟s foremost biotechnology and pharmaceutical companies.

The sale is line with MEPC‟s continuing strategy of releasing resources to focus on its large scale, mixed-use Estates. Under

MEPC‟s management Granta Park has grown into a leading science park with 99.8% of units let. Tenants include MedImmune, PPD Global, UCB Pharma and Vernalis (R&D).

Cambridge has become the premier centre for science in the UK and globally, and the success of Granta Park has been a significant contributor to accommodating many of Cambridge‟s leading bio-pharma companies. Granta Park is

now a world class science park which offers a superb position within the heart of the Cambridge science cluster; it is on the right side of Cambridge for London and is in close proximity to the

University of Cambridge, the Cavendish Laboratory, the Laboratory of Molecular Biology, the Sanger Institute and the Babraham Institute.

Rick de Blaby, Chief Executive of MEPC said: „Granta Park has been very important to MEPC over the last decade as a leading contributor

to our financial performance, and we are delighted that such a prestigious science park asset is passing on to a discerning investor. Our strategy is the continual development of our national

portfolio of large mixed used

Estates by means of recycling capital from the relatively stabilised and mature assets. Focussing on the large mixed use Estates

presents a huge opportunity for MEPC, as we know that we can drive sustained financial performance by applying our proven management style: focusing on customer care and developing an in-depth understanding of our

occupiers‟ needs.‟ „With our strong cash position, MEPC is also well positioned to capitalise further upon bank deleveraging in the UK market and, with our established management

platform, we will be seeking to acquire additional assets through the cycle.‟ Commenting on the sale, James Dipple, Director at MEPC added:

„Since its opening in 1998, we have successfully implemented our occupier focused management strategy to develop and grow Granta Park into the world-class

science park it is today. The sale of this robust asset is very much part of our ongoing strategy of releasing resources to focus on the

development and success of other large-scale Estates.”‟ Commenting on BioMed Realty‟s first international life science real estate investment, Alan D. Gold,

Chairman and Chief Executive

Officer, said: „We are extremely pleased and excited to announce our expansion of BioMed Realty‟s best-in-class property portfolio with

this investment in Cambridge, the premier

life science cluster in the UK and arguable all of Europe. The Cambridge market enjoys all of the critical elements that mark a strong, self-

sustaining life science

cluster, namely proximity to premier academic and research institutions, a highly skilled workforce, access to financial partners and a healthy portfolio of

strong commercial life science organisations.‟ Kent Griffin, President of BioMed Realty added: „Granta Park provides an

excellent investment opportunity with very attractive return potential consistent with our core business strategy – focused on highest-quality real estate in core life science clusters and in close proximity to primary demand

drivers, including leading research institutions. This recently developed, amenity-rich 11-building campus has attracted world-renowned life science research organisations and includes additional development potential,

enabling us to support their continued growth and expansion.‟ MEPC was advised during the agreement process by Jones Lang LaSalle on the investment sale,

Berwin Leighton Paisner LLP advised on corporate and tax law and BrookStreet des Roches on property law.

MEPC Sells Granta Park to BioMed Realty

21 October 2011 One Nucleus News October 2012 21

On 27 June, One Nucleus hosted

what has become an annual event

at the DoubleTree by Hilton,

Cambridge.

In an idyllic location overlooking

the punts on the Cam, 150

members attended the One Nucleus

Summer Social. It was a fantastic

opportunity to unwind on a

beautiful summer‟s evening and to

network with friends and colleagues

from the extended One Nucleus

family.

Thanks to the generosity of the

DoubleTree, we were treated to

some thirst-quenching Mojitos and

PIMMs whilst tucking into a hearty

barbeque.

For those of you interested in

supporting or attending the

Summer Social next year, please

save the date now – Wednesday

19 June 2013. See you there!

For more information please

contact Philip@onenucleus.com

The One Nucleus Summer Social BBQ and Mojitos on the Banks of the Cam

On 25 September, One Nucleus,

Cambridge Wireless and Sagentia

hosted a one day conference

entitled „Wireless Sensing in

Healthcare & Wellbeing‟.

With the rapid advancements in

wireless technology and its

increasing use in the healthcare

realm, this event gave industry

leaders the opportunity to share

perspectives on current and future

applications and address some of

the technical, operational and

ethical realities that lie ahead.

An excellent line up of speakers

included Sagentia‟s Senior Vice

President of Medical, Mick Withers;

Vice President of Surgical, Alistair

Fleming and Manager of Patient

Care, David Pettigrew. They were

joined by other industry leaders

including: Professor Chris Lowe,

University of Cambridge, Richard

Curry, SEHTA and Sybo Dijkstra

who is Head of the Hospital-to-

Home and Service Innovation

Group at Philips Research.

The day started with a selection of

informative presentations on topics

including Wireless Sensors in the

Healthcare R&D Environment;

Assisted Living and the Remote

Carer; Health Related Robotics; and

the Future of Patient Monitoring.

This was followed by a series of

workshops in the afternoon, giving

participants an opportunity to

discuss areas of collaboration and

exchange opinions on appropriate

next steps.

The 70+ delegates had a valuable

discussion and went away with new

ideas and contacts. We will be

following up on this one for some

time!

For more information about the

opportunities in this area, contact

Philip@onenucleus.com

Wireless Sensing in Healthcare and Wellbeing

What One Nucleus Does For You

22 October 2011 One Nucleus News October 2012 22

In recognition of our commitment

to offering good quality training to

the Life Science sector, One

Nucleus proudly became a

Corporate Affiliate of the CPD

Institute in June this year. This

now means that One Nucleus‟s

training courses count towards

Continuing Professional

Development (CPD) points / hours

demanded by professional bodies.

These points will contribute towards

the 40 hours of CPD required of the

individual for admission to the class

of Fellow of the Institute.

One Nucleus‟s training portfolio is

the largest of its kind in the UK and

our tailored courses are constantly

evolving. Listening to member

feedback, we will be introducing

some new material over the coming

months, including a Business

Development Academy, a course in

Change Management and

workshops on Smarter Working.

As always our trainers are selected

not only for their high quality

training skills, but also their

knowledge of the sector. Many of

them have firsthand experience in

companies within the Biotech and

Pharma industry, giving them the

knowledge to gear the course

structure and content to the ever

changing challenges we face.

One area which is growing in

popularity is the option to take any

of our courses „in house‟ with us

bringing the course to you.

Companies who have done this

have benefited from training being

tailored to suit their own specific

needs at a time and place to suit

their busy schedules.

If your company is committed to

maintaining a highly skilled

workforce, then look no further. For

more information about training

please contact me at

Philip@onenucleus.com

One Nucleus Training Portfolio Gains

Recognition from the CPD Institute

After three years of exciting

activities within a consortium of 13

of the most dynamic bioregions in

Europe, One Nucleus is now at the

end of its involvement in the

ABCEurope project which finished in

August 2012.

As a leading partner, One Nucleus

has been engaged in the

development and delivery of

several great initiatives, including:

Five Biotechnology showcases -

allowing researchers from

academia and commercial

organisations all over Europe, a

platform to present their

innovative technologies in the

fields of oncology, medical

technologies, infectious

diseases, e-health and

diagnostics;

Five bioentrepreneur boot

camps - held in different

European locations, giving 69

entrepreneurs the opportunity to

benefit from business specialist‟s

expert opinion and feedback on

how to improve their company

operations;

Three virtual business

matchmaking events - involving

a total of 62 companies from 11

different European countries in

partnering meetings with

potential new collaborators;

A „tool of science‟ platform -

which lists European facilities

and funding opportunities from

18 regions and provides new

business opportunities for R&D

companies and service

providers.

Although the overall project is now

complete, all these activities will

continue so we will keep you posted

on post-project actions.

Our involvement in ABCEurope has

been a great opportunity for One

Nucleus to develop closer

connections with other European

bioregions. As some of you will be

aware, we collaborated with

Medicon Valley Alliance, and

Stockholm-Uppsala Life Science on

joint activities for our members at

BIO2012 and we are in discussions

with a number of European clusters

about further information

exchanges and collaborations for

member benefit.

For more information on One

Nucleus‟ European activities please

contact aline@onenucleus.com

One Nucleus Activities in Europe

ABCEurope Conclusion

23 October 2011 One Nucleus News October 2012 23

I‟ve just hot-footed it back from my

first visit to AdvaMed. For those of

you who didn‟t attend, it took place

in Boston this year, last week.

The global healthcare industry is

clearly experiencing fundamental

transformation as it moves to a

value-based business. With

increasing demands from

consumers for enhanced healthcare

quality and increased value,

healthcare providers (and payers)

are clearly under pressure to

deliver better and more tangible

outcomes. This against a backdrop

of pressures to reduce costs and

improve co-ordination means that

times have perhaps never been

more trying for those involved in

the healthcare sector.

AdvaMed 2012 did a great job in

addressing the above, with top

quality panel sessions, CEO debates

and some critical political insights

(in advance of the first US

Presidential election live debate)

from two of CNN‟s liveliest

commentators Paul Begala (left

wing) and Alex Castellanos (right

wing).

I was expecting AdvaMed to be far

larger – not quite of the scale BIO

operates at but certainly one of

those events where you need flat

shoes, lots of energy and plenty of

Red Bull! In fact I really liked the

smaller nature of it - it was

exceptionally easy to navigate, to

meet the right people and to have

some very useful meetings both

with old friends and new. The

organisers claimed around 2,500

delegates and certainly the largest

AdvaMed to date. The UK

representation was by far the

largest from overseas, with over 50

UK companies taking part.

According to Anne Avidon, USA

Sector Lead for Healthcare at UK

Trade & Investment (UKTI): „We

were delighted to receive such a

positive response to the mission.

UK medtech companies are

accustomed to innovating in an

environment focused on clinical and

cost effectiveness. Taking costs out

of the system is the competitive

advantage that UK companies bring

to the US market‟.

UK Companies at AdvaMed

Some of the UK companies were

part of the FutureHealth (the

Health Tech and Medicines

Knowledge Transfer Network

organised) mission in collaboration

with the Technology Strategy

Board. 20 of the UK‟s most

promising healthtech companies in

the areas of stratified and

regenerative medicine, diagnostic

and assisted living technologies and

related solutions. For more

information check out:

www.futurehealthmission.com. The

clear message from the group is

that the US market is vast and

varied and understanding and

preparation are vital to your market

entry strategy. Their top tips for

working in the US health

environment are: do your research;

prepare to network; be US-literate;

Market Plan and Utilise resources

(learn from other company‟s US

experiences and talk with UKTI).

One Nucleus at AdvaMed 2012

Continued overleaf

‘It (AdvaMed) was exceptionally easy

to navigate, to meet the right people

and to have some very useful meetings

both with old friends and new’

24 October 2011 One Nucleus News October 2012 24

Talking of whom…..UKTI ran a

mission to AdvaMed as well – with

one of the top highlights being a

dinner at the Massachusetts State

House hosted by the new British

Consul General Susie Kitchens and

Lord Howe, Parliamentary Under-

Secretary of State at the

Department of Health. According to

AdvaMed officials: „The gala dinner

hosted by the Brits was the hottest

ticket in town, with CEOs, investors

and healthcare officials asking how

they could get a seat at the

table‟. Adds Anne: „The UKTI team

worked tirelessly to ensure that the

UK attendees maximised the

opportunity to make new contacts

and get deals done. One company

announced it expected to get £1

million in future revenue as a result

of introductions made at

AdvaMed.‟ One Nucleus members

in attendance included Sagentia,

Piramal Discovery Solutions and

Zoragen. The vibe was incredibly

positive. The mission was also

supported by Professor Sir Bruce

Keogh, Medical Director of the NHS

and a great opportunity for me to

reconnect with Sir Mike Rawlins,

the Chairman of NICE who retires

next year and I‟ve known for far

longer than either of us would care

to admit!

Messages from the Department

of Health

Earl Howe took part in a key panel

during AdvaMed where he had

some hard hitting messages for the

„standing room only at the back‟

audience. That:

Innovation has to be made core

business for the NHS;

There is a need to make the

NHS a more intelligent customer

with a greater dialogue with

business;

(in his opinion) there has never

been a better time for

innovators to engage with the

NHST;

He wants to create greater

consistency across the NHS;

Innovation is key to the future.

The panel (which included Guy

Lebeau Chair of Johnson & Johnson

and Eucomed) all readily agreed

that industry needs to be seen very

much as part of the solution, not

just a supplier.

AdvaMed: The Focus

For more information about

AdvaMed and to check out a new

set of industry messages that they

have created, click on

www.lifechanginginnovation.org.

The messages are supported by

sample proof points (which can be

found in the messages document of

the accompanying toolkit). The

emphasis being on:

Delivering value for patients;

Improving health system

efficiencies;

Contributing to economic growth

and leadership;

Securing public policies that

sustain patient access and

continued innovation.

One Nucleus Connections into

the US

For One Nucleus members looking

to connect with the medical

technologies sector in the US, do

remember that One Nucleus has a

formal (and tangible) relationship

with MassMedic. I took the

opportunity to catch up with their

CEO, Tom Sommer, who was

proudly sporting his One Nucleus

pin-badge when we met! See Page

3 for our interview with Tom. He is

able to offer a soft-landing for our

members looking to access the US

market and we offer the same to

his members. We also remain close

to Susan Windham-Bannister,

President of the Massachusetts Life

Science Center

www.masslifesciences.com and to

the Governor‟s office – some of you

may recall Governor Patrick‟s visit

to One Nucleus here in Cambridge

UK last year when he delivered his

keynote address in the UK on life

sciences in the presence of many of

our members. We enjoy keeping

these links very much alive and

working for our members.

‘One Nucleus has a formal (and

tangible) relationship with

MassMedic’

Harrie

t Fear, C

EO

One N

ucle

us, w

ith T

om

Som

mer, P

resid

ent M

assM

edic

25 October 2011 One Nucleus News October 2012 25

On the back of the Beecroft Report

- an entrepreneur‟s perspective on

how to set employers free - Vince

Cable has just announced his plans

to give businesses „flexibility and

confidence in managing their

workforce and to reduce

employment law red tape‟. They

include:

Settlement agreements to help

end employment relationships in

a fair and consensual way;

Reducing the cap on

compensation for unfair

dismissal claims;

Streamlining employment

tribunals by making it easier for

judges to dismiss weak cases.

Given these are all ways of making

it easier and less risky to fire

employees, it throws into sharp

relief what really concerns

employers: managing, and

sometimes ultimately dismissing,

employees who are

not performing or

who are no longer

needed - without

their organisation

being derailed in

the process.

Many small

employers can‟t

justify employing a

dedicated HR

professional to deal

with the human

side of their

business. Very

often it‟s the Chief

Executive‟s PA or

Finance Director

who gets

„personnel‟

wrapped up in their

brief. And even

organisations which

do have a

sophisticated HR

department need

help keeping up to

speed with

continual changes

in the law. One Nucleus members

span this broad spectrum, but

because they‟re all operating in the

same sector have many personnel

issues in common.

That‟s where the One Nucleus HR

SIG steps in. In conjunction with

Cambridge Employment Law LLP,

the One Nucleus HR SIG runs

quarterly meetings over lunch, with

the opportunity to network with

others dealing with HR in biotech

and pharma companies, and a

seminar focusing on an issue

relevant to the sector. Participation

is actively encouraged, with no war

story deemed too gory to share.

Recent subjects have included „The

Elegant Exit – how to manage an

employee out of the business with

minimum fuss and cost‟, and

„Managing Absence - how to deal

effectively with short-term,

persistent and long-term absence‟.

The subject of the next meeting on

18 October is a „Practical

Perspective on Maternity and

Paternity Rights - from risk

assessment to return to work‟. This

will be followed by our first meeting

of 2013 on 30 January. The

Government‟s proposed reforms

may well be on the agenda.

Sessions are run by Eleanor

Freeman, a very experienced

employment partner at CEL.

Eleanor has a commercial

background, having been an

international rights manager at

global publisher Dorling Kindersley

for six years before qualifying and

spending her early years as a

solicitor in the City. That City

experience and her subsequent

practice in Cambridge – as a

partner at Taylor Vinters before

leaving to co-found CEL LLP in 2011

- mean Eleanor has a highly

unusual combination of skills and

experience on which to draw when

advising clients … and a whole

range of great stories. She is also

steeped in the biomedical sector

having made this her focus since

arriving in Cambridge at the

beginning of 2005.

„I‟ve been running the One Nucleus

HR SIG sessions for a number of

years and thoroughly enjoy them.

For me, it‟s all about members

leaving meetings with a plan to

deal with individual problems that

may have been sucking up their

time - and worrying them - as well

as renewed confidence on how to

deal with the tricky issues which

crop up time and again. It‟s also

great for me to be able to build

long-term relationships with

practitioners outside the solicitor/

client nexus. I get to know people,

how they like to work and the

culture of their businesses, as well

as an inside track on what‟s

happening in the sector from the

HR perspective.‟

Eleanor Freeman

Cambridge Employment Law

HR Special Interest Group (SIG)

Ele

anor F

reem

an, C

am

brid

ge E

mplo

ym

ent L

aw

26 October 2011 One Nucleus News October 2012 26

One Nucleus currently has 50 Support Supplier Agreements (SSAs); 16 of these have been signed since March 2012 so as you

can tell, this is an ever-growing list, with a wide range of suppliers wanting to offer services to our members. Importantly these benefits can be accessed by ALL our members.

For the full list please see the Purchasing pages on the One Nucleus website or contact me at richard@onenucleus.com or on 01223 896453.

One Nucleus Support Suppliers

New Support Suppliers Since March 2012 Company SSA Contact Email Phone

365Force

Cloud Computing

Services Anil Vaidya Anil.vaidya@365force.com 02083 182468

Advanced Drving Techniques Ltd (ADT)

Driving Risk Management

Jim Golby Drjim.golby @applieddriving.co.uk

07768 776128

Black Swan Analysis

Business Analysis and Marketing Support Services

Christopher Ehinger

Christopher.ehinger @blackswan-analysis.co.uk

01628 621790

Crawford

Scientific

Chromatography

Products Lorraine Adams

Lorraine@

crawfordscientific.com 07767 227486

Edwards Vacuum

Vacuum Pumps and Services

Paul Raybolud Paul.Raybould @edwardsvacuum.com

07833 059309

Envirotainer Active Temperature Controlled Containers

Andy Holloway Andy.holloway @envirotainer.com

07920 513160

Fitnessworks Health, Fitness and

Wellbeing Solutions Dave Southby Info@fitnessworks.co.uk 01223 870077

GoIndustry DoveBid

Redundant Asset Management Services

Peter Cauldwell peter.cauldwell@go-dove.com 07774 417227

Haseltine Lake LLP Intellectual Property Services

David Hammond dhammond@ haseltinelake.com

01179 103200

Hyper Recruitment Solutions (HRS)

Recruitment Services Ricky Martin ricky.martin@hyperec.com 02032 255121

JoVE Journal of Visualized Experiments

Frank Buckley Frank.buckley@jove.com 0016172 450152

La Playa Insurance and Financial Management

Matthew Clark matthew.clark@ laplayainsurance.com

01223 200667

ProsimFX International Payment

Systems Neville Holmes

neville.holmes@

prosimfx.com 02030 110200

Realnet Ltd Website Services Dan Orme Dan.orme@realnet.co.uk 01223 261109

Specialized Print

Ltd

Corporate

Printing Services Ann Aken ann@specialized-print.co.uk 01440 708063

Venture Market Intelligence

Venture Market Database

Burak Alpar Burak.alpar@ vmindex.com

02035 140710

27 October 2011 One Nucleus News October 2012 27

Don‟t forget that One Nucleus

offers Facilities Management

consultancy to members at a

discounted rate.

Richard Dickinson Director of

Specialist Services, has 15 years‟

experience as a Facilities Manager

and has worked for more than 20

years in the life science sector.

Richard provides project

management for office and

laboratory fit-outs and can help

with equipment service contracts,

maintenance contracts, cleaning

contracts, utility bills, insurance,

purchasing and budgeting.

Currently working for Cantab

Biopharmaceuticals he has

previously consulted for a number

of One Nucleus members on

various different projects including

Astex Therapeutics Ltd, Pathology

Diagnostics, Babraham Bioscience

Technologies Ltd, Zoragen

Biotechnologies, Spirogen Ltd and

Fahy Gurteen Laboratories.

For more information on Facilities

Management please contact Richard

at richard@onenucleus.com or on

01223 896453.

One Nucleus Facilities Management

On 17 September a delegation of

17 arrived in Cambridge for two

days of events co-hosted by One

Nucleus and Cambridge Cleantech,

and sponsored by the Hong Kong

Science & Technology Parks

(HKSTP). The delegation included

representatives of HKSTP, Hong

Kong based companies and officials

from Hong Kong and mainland

China.

A VIP reception gave the visitors a

chance to meet the great and the

good of the Cambridge CleanTech

and Life Science communities.

Guests included Sir Paul Judge,

Alan Barrell, and Charles Cotton of

Cambridge Phenomenon fame.

There was also a special guest, Sir

John Bradfield, the founder, here in

Cambridge, of the first science park

in Europe.

After the reception there was a

dinner for 100 invited guests in the

candlelit Hall at Magdelene College,

where the diners were entertained

by Sir Paul Judge with his after

dinner speech.

The main event was a conference

at Cripps Court where 150 people,

including some One Nucleus

members learnt about the

opportunities for Life Science and

Cleantech companies in Hong Kong

and China. One startling statistic is

that China‟s ageing population is

growing faster than anywhere else

in the world, and that by 2050,

45% of the Chinese population will

be over the age of 65. That is

compared to only 15% today. The

healthcare needs of these people

will be enormous.

Speakers at the event included

senior Chinese official Peng Jimin,

Senior Economist from the National

Development and Reform

Commission (NDRC) in China and

Janette Evans, Executive Director

(Corporate Business) at

Astrazeneca. AZ consider China to

be the most important pharma

growth area at the moment, for the

reasons mentioned above.

For more information on the

opportunities in Hong Kong and

China, contact Philip at

Philip@onenucleus.com

Exploring the China Opportunity

Ala

n B

arre

ll, Bjö

rn S

egerb

lom

, Sir P

aul

Judge, M

artin

Garre

tt and P

hilip

Kendall

Peng Jim

in, S

enio

r Econom

ist N

DRC

28 October 2011 One Nucleus News October 2012 28

One Nucleus and our Programme

Partners, SCRIP Intelligence, invite

executives from the global life

science industry to register to

attend the 2012 Genesis

Conference, taking place in

London‟s prestigious Queen

Elizabeth II Conference Centre on

Thursday 13 December.

There is a great deal written about

such topics and the need for

greater efficiency in the discovery

and development of new medicines,

the increasing regulatory barriers,

emerging markets, innovative

deals, industry globalisation, CROs

sharing risk, Government

interventions and the lack of

venture finance to name just a few

of the challenges and opportunities

facing today‟s life science

executives.

There are numerous conferences,

webinars and speeches delivered

that all provide a degree of

facilitation for executives to learn

from their peers, instigate alliances

or present to investors. However,

there are very few conferences for

650+ delegates that create and

environment where each delegate

can go away feeling they have had

an education in the roadmap to

success through a critique of their

peers‟ deal making, business

models and hearing others‟ future

visions of the industry‟s on top of

the traditional 1-2-1 meetings,

networking and experience.

After more than a decade of

success, Genesis is stepping up a

gear this year. Our collaboration

with Scrip Intelligence will provide

pre-conference commercial

intelligence by therapeutic area,

design a programme format to give

a global presentation of the

industry from a UK perspective and

increase our reach to the top

Pharma and investment executives

to engage them in the debate.

Genesis 2012 will be truly thought

leading. Identifying and addressing

the issues that really matter, with a

programme that is educational,

inclusive and provocative, making

this year‟s Genesis a must-attend

event.

The conference, debate and

showcase on the theme of

„innovative strategies to bridge the

R&D gap‟ will include:

An opening plenary session, with

keynote speakers setting the

scene and identifying challenges

from policy, early stage

innovation, later stage growth

and deal success perspectives;

Parallel leadership sessions,

focused by therapeutic or

technology areas, where case

studies of deals, financings and

collaborations will be showcased

and debated. The 90 minute

sessions will cover: CNS,

oncology, infectious diseases,

inflammation and respiratory

disease, cell-based technologies

in R&D, Alternative

Therapeutics, Open Innovation

and a UK Showcase debating

what the UK has to offer

domestic and international life

science businesses;

A closing plenary debate and

reception, where feedback from

the day‟s sessions will inform

panel discussions as we look to

develop a „Roadmap to Success

for 2013‟;

Genesis Conference 2012: A step change

in delegate engagement

Continued overleaf

29 October 2011 One Nucleus News October 2012 29

A VIP Stakeholder Reception –

replacing the traditional gala

dinner awards, this year we are

reaching out to the executives

from the wider healthcare field

such as patient advocacy

groups, NGOs, policymakers and

NHS commissioning groups. We

will be inviting their senior

personnel as guests to the

plenary debate and networking

reception in order to encourage

greater dialogue and

collaboration between those

groups with a role in delivering

future healthcare.

Not to mention:

Pre-conference intelligence from

SCRIP, to inform delegates and

stimulate discussion

A Welcome Reception at the

recently refurbished Canada

House, courtesy of the Canadian

High Commission on the evening

of Wednesday 12 December

1-2-1 partnering

International exhibition

The parallel sessions within Genesis

are purposefully designed to map

on to the Life Science Leadership

Series themes we have launched

since their creation in 2011. This

includes engaging our world class

advisory boards from those

themes, comprising senior

executives from the following

organisations: AstraZeneca,

BioMedical Partners, Cancer

Research Technologies, Eli Lilly,

EOLAS, Future Injection

Technologies, GE Healthcare,

Lab21, Medimmune, Merck, MS

Therapeutics, Pathology

Diagnostics, Pharmidex, Senexis,

TWI and Vision RT with more being

added as the themes expand.

Join the expected 650+ delegates:

book your place at this unique

forum today. Delegate rates start

from just £195 + VAT (Exhibitor

fees from £1,100 + VAT) and can

be booked now at

www.onenucleus.com/genesis-2012

For more information on Genesis

please contact

Tony@onenucleus.com

Isn‟t it great when you attend a

networking meeting, leadership

event or conference and one of the

speakers or other delegates gives

you just the right information to

help you steer a better course of

action to address current problems.

The reverse is true too, of course,

when the conversation at that

meeting seemed irrelevant at the

time only to find at a later date the

information would have been key

and you are left scouring the

depths of your memory to recall

who it was that was speaking. Fear

not! Our latest initiative, the One

Nucleus Dashboard creates the

virtual reality of making that earlier

networking event available 24/7 to

members facing the practical

challenges of managing a growing

life science business.

To be launched in the near future,

the Dashboard will be a one-stop-

shop helpline for easily accessible

advice from selected experts across

a variety of specialised areas.

These specialist areas will include:

Commercial Intelligence;

Corporate and Commercial Law;

Executive Recruitment and

Interim Support;

Facilities Management;

IP Strategy;

Logistics;

Marketing and Communications;

National and EU Grant Funding.

Overall the Dashboard allows for

better and more timely sharing of

expertise between members

through an online enquiry function

directed straight to the appropriate

expert who will provide a timely

answer direct to your inbox. This

will allow members to seek the sort

of rapid expert guidance you would

expect to find when meeting at a

networking event or conference.

The Dashboard will also provide

members with accessible news

feeds from our approved experts to

stay abreast of industry

developments such as regulatory

changes, funding calls and new

services.

For more information on the One

Nucleus Dashboard please contact

Tony@onenucleus.com

Navigating members to the right information at

the right time with the One Nucleus Dashboard

30 October 2011 One Nucleus News October 2012 30

The majority of One Nucleus

members that attended BIO were

undoubtedly focused on the 1-2-1

partnering activity with odd forays

into the wider exhibition hall for

more general networking, pavilion

receptions or to simply touch base

with their home country base at the

UK Pavilion. 2012 was the first time

BIO had located the 1-2-1 Business

Forum in the centre of the

exhibition hall. I think there was

universal acceptance that this

enhanced the experience for the

exhibitors, being able to arrange

client meetings at their own stand

and hence maximise the return on

their investment of attending.

Prior to Boston, One Nucleus had

been instrumental in ensuring Rt

Hon David Willetts MP, Minister for

Universities & Science, was

nominated for the 2012 BIO

International Leadership Award

which he was awarded during the

convention. Accepting the award

the Minister commented „It is a real

honour to be presented with the

BIO International Leadership Award

and to have the UK‟s work to

support the life sciences industry

recognised internationally. Our life

sciences sector is world-class, but

we are not complacent. It‟s vital we

respond to global changes in the

industry with more focus on

collaboration and more prompt

clinical trials. We want to ensure

the industry continues to drive

growth, foster innovation and

attract overseas investment.‟

Winning the award, recognising the

work by the stakeholders behind

the Life Science Strategy, was an

excellent opportunity to ensure the

UK was placed firmly in the shop

window which can only be good

news for our members.

One Nucleus focused its proactive

member engagement on two

events at the start of the period in

Boston, both in collaboration with

our US-based MOU partners and a

Scandinavian partner.

Sunday, 17 June

An Executive Dinner in

collaboration with MassBIO,

MassMEDIC and MVA sponsored by

Covington & Burling LLP attracted

50 attendees from the large

Pharma, biotech, medical

technology and CRO base of the

three regions. There was no fixed

agenda, more opportunity for

industry leaders from three

geographical regions to learn

informally from each other about

key trends, initiatives and market

opportunities in the other key

territories present.

Monday 18 June

A strong research infrastructure backed by leading research universities and institutes are key

elements in a leading life science cluster. This was one of the messages at a breakfast seminar entitled „If we build it they will come‟.

The breakfast seminar was

arranged by Stockholm-Uppsala

Life science and One Nucleus

(London/Cambridge life science

cluster) for invited media and other

guests. Rob Johnson (Alacrita

Consulting) acted as chairman for a

panel with Joe Panetta (BIOCOM),

Michael Capaldi (Edinburgh

BioQuarter),Torbjörn Bjerke

(Karolinska Development) and

Kevin Mullin (City of South San

Francisco). The audience consisted

of an additional 30 experts from

companies, press and cluster

support groups.

In addition to a strong research

base, other assets considered by

the panellists as important for

attracting companies are capital,

venture capital and government

funding, a pool of talent and

entrepreneurs, an efficient

technology transfer system and a

supportive local government were

deemed important. Proximity to

academic institutions and to

international airports also being

important. Favourable public

policies and supportive measures

such as tax benefits and

infrastructure programs (roads,

public transportation and utilities)

are other factors that make clusters

more attractive.

Another theme discussed was

collaboration. „ It‟s really important

that clusters come together and

work with each other. A few key

clusters networked together

supervising cross-collaboration, for

instance around certain disease

areas has a lot of value‟, said

Chairman Robert Johnson.

„I think events like this breakfast

seminar are important for fostering

collaboration, said Torbjörn Bjerke,

Karolinska Development. We share

many of the same challenges and

opportunities in order to create new

companies and if we can

collaborate, I very much believe

that we will have a stronger

biopharmaceutical and biotech

community in the future.‟

For more information please

contact Tony@onenucleus.com

BIO2012

Massachusetts

Govern

or D

eval P

atric

k a

ddre

sses

onlo

okers

at B

IO2012

31 October 2011 One Nucleus News October 2012 31

Jerry

Walk

er, C

EO

Inte

lligent F

ingerp

rintin

g

As many of our regular readers will

know, the Life Science Leadership

Series (LSLS) was our innovative

strategy to replace the longer and

more general Cambridge Partnering

Conference in response to member

feedback. These one day events,

focussed by therapeutic or

technology area, attract up to 150

delegates as a maximum allowing

well informed debate and effective

networking.

Since we last reported, there have

been four subsequent events,

including the launch of out two

latest thematic foci: Infectious

Diseases & Vaccines (May 2012)

and Personalised Medicine (Sept

2012).

May saw 120 delegates gather for

our Infectious Diseases & Vaccines

leadership event where the

programme was opened by Tim

Wells of Medicines for Malaria

Ventures who presented the global

challenges presented by infectious

diseases before narrowing to focus

on their partnerships in malaria. No

-one should under-estimate the

challenges, and thus by correlation

the market opportunity, although

this is likely to best be addressed

through collaborations and

alliances, possibly under PPIs, than

by individual companies. This was

complemented by the two other

plenary presentations.

David MacIntosh (Novartis) setting

out the various challenges and

previous successes over Seven

Ages of Man’ and Professor Sir

Anthony Coates who described the

innovative approach of targeting

dormant bacteria being undertaken

at the Antibiotic Discovery Centre

at St George‟s University of

London. Sir Anthony finished with a

call to arms to industry and

academic parties to join his vision

to rebuild the process of antibiotic

discovery by joining his Antibiotic

UK initiative. In between the

opening and closing plenary

sessions, there were case study

presentations from emerging

companies all at the early stages of

drug discovery and development of

new anti-infective agents.

Companies including Discuva,

NovaBiotics, Phico Therapeutics and

Biotica highlighted their technology

approach and partnering goals.

September has seen an evolution of

the Healthcare Technologies theme

launched in 2011. Spinning out

from the initial theme was a follow-

on seminar hosted by TWI,

focussed on building value in

medical technology companies. The

opening plenary presentations from

Paul Sherrat (TWI) and Tony Cass

(Imperial College) looked to the

past and future, respectively, to set

the context for the following

sessions. Paul covered some of the

lessons learned from the past

seven decades of commercialising

innovation whilst Tony looked to

the emerging field of biosensors in

the mobile world that will shape

how we manage and treat

healthcare conditions in the years

to come. Following the scene

setting above, a line up of

experience medical technology

industry executives stimulated

debate on what the challenges for

growth in the biosensor and IVD

market, innovation and use of

smart materials and the funding

and commercial opportunities

represented by UK Government

support, private investors and

emerging Asian markets.

More recently, the September 2012

LSLS event focused on Advances in

Personalised Medicine. The

increasing importance of

biomarkers and diagnostics in

diseases detection, patient

management and clinical trials

means the demand for technologies

that can selectively and

reproducibly quantify the detection

of such biomarkers continues to

grow. A number of commentators

and industry executives are starting

to suggest that in maybe as little as

five years, the regulators such as

FDA and EMA will require the

companion diagnostic to be

available before a new drug will be

approved. This will mean continued

integration of the appropriate

disciplines such as diagnostic

validation, bioinformatics, medicinal

chemistry and pharmacology will be

required to develop new

therapeutic entities. The wider

context of such inter-dependent

approaches has potentially far

reaching implications.

Life Science Leadership Series

Continued overleaf

Eddy L

ittler, C

EO

Dom

ain

ex

32 October 2011 One Nucleus News October 2012 32

The event opened with opened by

plenary presentations from

Professor Munir Pirmohamed,

University of Liverpool describing

how advances in pharmacogenetics

will shape how patients and new

medicines will be viewed as we s

eek to streamline treatment

strategies and pathways . This was

followed by Bob Holland of Astra

Zeneca presenting how his

company is making personalised

medicine technologies such as

biomarkers, companion diagnostics

and pharmacogenetics a

mainstream activity in all new R&D

programmes.

Far from only focussing on the post

-development use of companion

diagnostics and biomarkers, the

day also included a series of case

study presentations highlighting the

role of these platforms in the entire

R&D process, including discovery of

novel therapeutic targets,

enhancing key decision making

through surrogate end points and

product rescue by better patient

selection during clinical trials.

Much like the 2012 Olympic and

Paralympic Games, it was always

the intention that the LSLS were

not stand alone events, but were

the catalyst for a legacy. The

targeted form of legacy includes:

Follow on seminars;

Microsites linking off the main

One Nucleus web site that will

contain focussed archives of

presentations and opinion leader

articles and news relevant to

that therapeutic area;

The opportunity for larger

advisory firms, CROs and R&D

organisations to engage in a

targeted manner via our Partner

Programme, highlighting their

key value proposition and

competencies through a focused

exemplification in one leadership

area.

Turning to each of the targeted

legacy items, we are delighted to

be able to demonstrate success on

all three. There have been follow-

on events in the Oncology, CNS and

Healthcare Technologies themes

already. Oncology has included

events that have showcased

innovative technology companies,

open innovation and international

collaborations through events

hosted by Charles Russell LLP and

the Australian High Commission

through life Sciences Queensland.

The first CNS follow-on event in

May 2012 saw the VP Neuroscience

at Eli Lilly describe how the next

year would be key to

demonstrating, or not as it turns

out, the success of targeting Beta-

amyloid due to critical trials falling

due to report. Mike Hutton then

went on to suggest new approaches

were moving through such

evaluation such a targeting the Tau

protein and inflammatory pathways

connected to neurodegeneration.

The same event, hosted be

Eversheds and sponsored by QPS,

included presenters from

Netherlands, Singapore and Norway

where the over-riding impression

left was that international

collaboration was essential to

deliver success in such complex

diseases areas as Alzheimer‟s

diseases. Moreover, it also

highlighted why companies should

consider geographical regulatory

environments when planning where

to perform the various parts of the

pre-clinical and subsequent clinical

development.

The development of the thematic

microsites to enable these

therapeutic or technology platform

area sub-communities to continue

the debate, sharing their thoughts

and news with peers has continued

within One Nucleus. The microsites

will launch this [Autumn – HF to

confirm] and will host the LSLS

presentations, talking head videos

from the advisory board members

and key speakers and an archive of

relevant reviews and news articles.

Finally, we are pleased to announce

Charles Russell LLP as the first One

Nucleus Partner to join under our

proposal to highlight their strengths

through leadership theme

examples. Of course, their service

offer applies across the life science

technology space and wider,

however a good example of such

engagement was the presentation

given by Jennifer Pierce at our

October 2011 oncology seminar on

„Future proofing deals‟. Jennifer

shared her experience of what

happens when IP licensees go

through M&A for example and how

to take a balanced and pragmatic

strategy to protecting yourself in

such a dynamic business

environment.

For more information please

contact Tony@onenucleus.com

33 October 2011 One Nucleus News October 2012 33

Being aware of the increasing

interest in translational research as

pivotal for the delivery of

tomorrow‟s healthcare, One

Nucleus is delighted to announce

the creation of a brand new event

aiming at supporting organisations

and businesses involved in this vital

and exciting field.

This one day event aims to inform

delegates of how to turn early

stages inventions and ideas into

innovative health treatments (new

medicines, novel biomarkers, useful

medical devices or improved

medical practices).

It will present the UK landscape of

the business environment, funding,

scientific and clinical research

excellence and will be a unique

knowledge-sharing environment

between academia and business.

Together with an outstanding

Advisory Board, we are designing

an exciting programme including

case studies discussions,

technologies presentations and

practical information with as usual,

plenty of space for networking.

Advisory Board members:

Sir Bruce Ponder Cancer

Research UK

Ruth McKernan, CSO Neusentis /

SVP Pfizer

Jackie Hunter, CEO OI Pharma

Partners

Jon Green VP MedImmune and

One Nucleus Chair

Alan Palmer, CSO MS

Therapeutics and One Nucleus

Board member

Jane Dancer, COO F-Star

Harriet Fear, CEO One Nucleus

Sue Dunkerton, Co-Director

Healthtech & Medicines KTN

Geoff Lawton, Director INMedD

Dave Tapolczay, CEO MRC T

More information will be available

soon but if you or your organisation

would like an early heads-up on the

opportunities this event will afford,

do feel free to contact Aline at

Aline@onenucleus.com

New One Nucleus Conference – Save the

date! ON Helix – 9 July 2013. Wellcome Trust Genome Campus in Hinxton

34

One Nucleus Sponsors

Corporate Patron

Corporate Sponsors

October 2011

Partners

Media Partners

34 October 2011 One Nucleus News October 2012 34

Date Event Venue

24-Oct-12 Network Meeting Deloitte, Cambridge

07-Nov-12 BioWednesday Charles Russell,

London

21-Nov-12 Network Meeting Stevenage

Bioscience Catalyst

13-Dec-12 Genesis 2012

QEII Centre,

Westminster, London

19-Dec-12 Pub Social Cambridge

09-Jan-13 London Pub Social London

23-Jan-12 Life Science Leadership Series: Antibodies and

Protein Based Therapeutics

Babraham Research

Campus

06-Feb-13 BioWednesday London

27-Feb-13 Network Meeting Cambridge

06-Mar-13 BioWednesday London

New Members

365Force

A4P Bioanalytical Group

Almagen Ltd (BBT prog)

Amadeus Capital Partners Ltd

AnGes Euro Ltd

APL

Applied Driving Techniques

Argon Design Ltd

Ariel Pharma (Europe) Ltd

Biotec Services International Ltd

CamNutra Ltd

CK Clinical

Clariant

College Hill Life Sciences

Crawford Scientific

Dehns

Diasolve Ltd

Dr Nicky Thelwell

Edwards Ltd

Entrepreneurs Fund Management

Envirotainer AB

Fitnessworks Management

Services

GoIndustry (UK) Ltd

Haemostatix Ltd

Health Enterprise East

Hyper Recruitment Solutions

IRON Recruitment

Journal of Visualized Experiments

Labstract Ltd

MDM Asia

Mercury Pharma

MVM Life Science Partners LLP

NovaSecta Ltd

Novus Environmental

OctoPlus NV

Oncology Pharma

PCR Biosystems

Pharmonyze Ltd

Phico Therapeutics

Political Intelligence

PPR Diagnostics

ProPharma Partners Ltd

ProsimFX Ltd

QRC Consultants Ltd

ReAgent Ltd

Realnet Ltd

Reed Scientific

Specialized Print Ltd

to-BBB technologies BV

Transpharmation

University of Reading Academic

Legal Services

Vectura Plc

Vertex Pharmaceuticals

WIL Research

One Nucleus Events to Spring 2013